Publications Database

Akhondzadeh S. et al. (2010)

Double-blind placebo controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism.

Progress in Neuro-Psychopharmacology and Biological Psychiatry

34(1), pp. 32-36

Read Abstract (New Window)

Becker M. M. et al.

Improvement in symptoms of autism spectrum disorder in children with the use of gastrin-releasing peptide: An open trial.

Clinical Neuropharmacology

Read Abstract (New Window)

Boris M. et al. (2007)

Effect of pioglitazone treatment on behavioral symptoms in autistic children.

Journal of Neuroinflammation

4(3),

Read Abstract (New Window) Read Full (New Window)

Boris M. , Goldblatt A. , Edelson S. M. (2006)

Improvement in children with autism treated with intravenous gamma globulin.

Journal of Nutritional and Environmental Medicine

15(4), 169-176

Read Abstract (New Window) Read Full (New Window)

Bradstreet J. J. et al. (2007)

Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders.

Medical Hypotheses

68(5), pp. 979-987

Read Abstract (New Window) Read Full (New Window)

Brockett S. S. , Lawton-Shirley N. K. , Kimball J. G. (2014)

Berard auditory integration training: Behavior changes related to sensory modulation.

Autism Insights

Read Abstract (New Window) Read Full (New Window)

Canitano R. , Scandurra V. (2008)

Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents.

Neuropsychiatric Disease and Treatment

4(4), pp. 723-730

Read Abstract (New Window) Read Full (New Window)

Capone G. et al. (2008)

Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study.

Journal of Developmental and Behavioral Pediatrics

29(2), pp. 106-116

Read Abstract (New Window)

Cheng Y. et al. (2017)

Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders: a meta-analysis of randomized controlled trials.

Neuropsychiatric Disease and Treatment

13 pp. 2531–2543.

Read Abstract (New Window) Read Full (New Window)

Edelson S. E. (1990)

The candida yeast-autism connection

San Diego, CA: Autism Research Institute

Erickson C. A. et al. (2014)

STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

Journal of Autism and Developmental Disorders

44(4), pp. 958-964.

Read Abstract (New Window)

Fatemi S. H. (1998)

Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial

Journal of Autism and Developmental Disorders

28(4), pp. 303-307

Read Abstract (New Window)

Fido A. , Al-Saad S. (2008)

Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.

Medical Principles and Practice

17(5), pp. 415-418

Read Abstract (New Window)

Gabriels R. L. et al. (2012)

Pilot study measuring the effects of therapeutic horseback riding on school-age children and adolescents with autism spectrum disorders.

Research in Autism Spectrum Disorders

6(2), pp. 578-588

Read Abstract (New Window)

Ghaleiha A. et al. (2013)

Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.

Journal of Psychopharmacology

October, 28(7), pp. 677-685.

Read Abstract (New Window)

Ghaleiha A. et al. (2013)

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial.

Pediatric Drugs

15(6), pp. 505-514.

Read Abstract (New Window)

Ghanizadeh A. , Sahraeizadeh A. , Berk M. (2014)

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.

Child Psychiatry and Human Development

45(2), pp. 185-192.

Read Abstract (New Window)

Matson J. L. , Hess J. A. (2011)

Psychotropic drug efficacy and side effects for persons with autism spectrum disorders.

Research in Autism Spectrum Disorders

51

Read Abstract (New Window)

Miyaoka T. et al. (2012)

Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.

BMC Psychiatry

12 pp. 215.

Read Abstract (New Window) Read Full (New Window)

Owley T. et al. (2006)

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 517-552

Read Abstract (New Window)